Last reviewed · How we verify
Ultra Rapid Lispro (URLi)
Ultra Rapid Lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Ultra Rapid Lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Ultra Rapid Lispro (URLi) |
|---|---|
| Also known as | Lyumjev |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
URLi is a modified form of insulin lispro designed with faster absorption kinetics through the addition of nulisinon (a surfactant) and citrate, enabling more rapid onset of action compared to standard insulin lispro. This allows for improved postprandial glucose control with dosing closer to meal initiation in patients with diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultra Rapid Lispro (URLi) CI brief — competitive landscape report
- Ultra Rapid Lispro (URLi) updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI